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NSAIDs and atrial fibrillation
The risk is unproved, but NSAIDs should be used with caution in high risk patients anyway
Jerry H Gurwitz professor of medicine and executive director
Meyers Primary Care Institute, a joint endeavour of Fallon Clinic, Fallon Community Health Plan and University of Massachusetts Medical School,
Worcester, MA 01609, USA
More than two million Americans and more than four million
people in the European Union have paroxysmal or persistent
atrial fibrillation.1 Its prevalence increases dramatically with
advancing age, rising from 0.1% in adults younger than 55 years
to 9.0% in those aged 80 or more.2 Atrial fibrillation is
associated with an increased long term risk of stroke, heart
failure, and death. The healthcare costs related to this condition
are substantial, largely as a result of hospital admissions,
consultations, diagnostic and therapeutic procedures, and drug
treatments. Many patients with atrial fibrillation need lifelong
treatment with oral anticoagulants for stroke prevention, which
requires careful dosing and laboratory monitoring; safety
concerns about the risk of bleeding persist for these patients
even under the most ideal systems of care. For these reasons,
any opportunity to reduce the risk of atrial fibrillation,
particularly in older adults, would be welcome. In the linked
case-control study (doi:10.1136/bmj.d3450), Schmidt and
colleagues describe an association between the use of
non-selective non-steroidal anti-inflammatory drugs (NSAIDs)
or selective cyclo-oxygenase-2 (COX 2) inhibitors and atrial
fibrillation or flutter.3
In 2008, an expert panel convened by the National Heart, Lung,
and Blood Institute highlighted that although treatments for
atrial fibrillation have been studied extensively, prevention has
received relatively little attention.4 Modifiable risk factors
include hypertension, diabetes, obesity, and smoking.5
Predisposing clinical conditions include heart failure, myocardial
infarction, valvular heart disease, thyroid disease, and sleep
disordered breathing. These risk factors and predisposing
conditions probably interact with various non-modifiable risk
factors including age, sex, race, and genetic factors.
The identification of drug related precipitants of atrial fibrillation
adds an interesting new dimension to its prevention.6 Using
administrative data for a Danish population from 1999 to 2008,
Schmidt and colleagues examined the risk of atrial fibrillation
or flutter associated with the use of non-selective NSAIDs or
selective COX 2 inhibitors.3 After adjustment for age, sex, and
selected risk factors for atrial fibrillation, they found a significant
increase in the risk of atrial fibrillation or flutter with current
drug use compared with no use (non-selective NSAIDs: adjusted
odds ratio 1.17, 95% confidence interval 1.10 to 1.24; COX 2
inhibitors: 1.27, 1.20 to 1.34). Risks were greatest for new users
compared with non-users (non-selective NSAIDs: 1.46, 1.33 to
1.62; COX 2 inhibitors: 1.71, 1.56 to 1.88), but much less strong
for long term users compared with non-users (non-selective
NSAIDs: 1.05, 0.98 to 1.13; COX 2 inhibitors: 1.10, 1.03 to
1.18).
An association between use of NSAIDs and atrial fibrillation
has important clinical and public health implications because
of the high prevalence of use of these agents, particularly among
older adults, and the increasing prevalence of atrial fibrillation
with advancing age. The validity of the study’s findings must
be carefully considered, however, because case-control studies
are susceptible to unmeasured confounders, potentially limiting
the inferences that can be drawn from the results.7 Adjusting
for covariates modestly reduced the strength of the associations
between the use of non-selective NSAIDs and COX 2 inhibitors
and atrial fibrillation or flutter. However, Schmidt and
colleagues lacked data on several important clinical measures,
such as body mass index. Obesity is strongly associated with
osteoarthritis,8 9 one of the most common indications for
treatment with NSAIDs. This unmeasured confounding variable
could have affected the study’s findings, because obesity is an
established risk factor for atrial fibrillation. Schmidt and
colleagues’ efforts to estimate the effects of a hypothetical
confounder only partially allay these concerns about unmeasured
confounding.
The current study is not the first case-control study to report an
association between the use of NSAIDs and atrial fibrillation.
A study that used data from the United Kingdom General
Practice Research Database found that current use of NSAIDs
was associated with an increased risk of atrial fibrillation, yet
the results of that study differed from the current findings in
that risk was greatest for long term users rather than for new
users.10 In both studies, the dose-response relation was not
consistent, which makes the association even more tenuous.7
The association between NSAIDs and atrial fibrillation does
not imply a cause and effect relation. One proposed explanation
for the association is: “the existence of an underlying
inflammatory condition, increasing the risk of AF [atrial
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fibrillation] on the one hand and prompting the use of NSAIDs
on the other.”10 Perhaps a more likely scenario is that these
agents trigger or exacerbate clinical conditions, such as heart
failure and hypertension, that lie along the causal pathway of
atrial fibrillation.
What should clinicians do in practice in the light of current
evidence? With uncertainty regarding a plausible biological
mechanism, the susceptibility of case-control studies to
unmeasured confounders, and inconsistent results in the two
studies performed to date, a cautious approach seems warranted
in applying the study’s results to the care of patients. However,
NSAIDS (non-selective NSAIDs and COX 2 inhibitors) should
continue to be used very cautiously in older patients with a
history of hypertension or heart failure, who are already at high
risk for adverse effects of these drugs, regardless of whether an
association between NSAIDs and atrial fibrillation actually
exists.
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